Literature DB >> 23784316

Maternal Phenylketonuria International Collaborative Study revisited: evaluation of maternal nutritional risk factors besides phenylalanine for fetal congenital heart defects.

Shoji Yano1, Kathryn Moseley, Teodoro Bottiglieri, Erland Arning, Colleen Azen.   

Abstract

Maternal phenylketonuria (MPKU) is known to affect fetal outcome, often being associated with microcephaly and congenital heart defects (CHD) if the maternal diet is not appropriately managed. We hypothesized that other nutrients aside from phenylalanine (Phe) may have significant effects on fetal outcome in MPKU pregnancies. The 416 pregnancies that resulted in live births reported in the Maternal PKU Collaborative Study (MPKUCS) were grouped according to whether or not the offspring were diagnosed with CHD. The groups were compared on first-trimester values of maternal data, including weight gain, plasma amino acids, protein and Phe intake, and red blood cell (RBC) folate. Patients were also grouped by first-trimester average blood Phe (≤910 μmol/L and >910 μmol/L) and then divided by total natural protein and medical food intake. The CHD group of 28 offspring had significantly higher blood Phe and lower proline, valine, methionine, isoleucine, leucine, lysine, arginine, and RBC folate. A significantly higher risk for CHD was found in the groups with lower natural protein and medical food intake, regardless of blood Phe levels. Insufficient natural protein and medical food product intake appears to be a risk factor for CHD independent of first-trimester plasma Phe levels. Low RBC folate and plasma methionine levels in the CHD group may suggest involvement of global DNA hypomethylation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23784316      PMCID: PMC8889884          DOI: 10.1007/s10545-013-9627-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss Of response in tumor cells.

Authors:  W A Campbell; D E Sah; M M Medina; J E Albina; W B Coleman; N L Thompson
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

2.  Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase.

Authors:  Qingping Feng; Wei Song; Xiangru Lu; Joel A Hamilton; Ming Lei; Tianqing Peng; Siu-Pok Yee
Journal:  Circulation       Date:  2002-08-13       Impact factor: 29.690

Review 3.  Phenylketonuria.

Authors:  Nenad Blau; Francjan J van Spronsen; Harvey L Levy
Journal:  Lancet       Date:  2010-10-23       Impact factor: 79.321

4.  Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAHENU2 mice.

Authors:  Kara R Vogel; Erland Arning; Brandi L Wasek; Teodoro Bottiglieri; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

5.  Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Authors:  J Pietz; R Kreis; A Rupp; E Mayatepek; D Rating; C Boesch; H J Bremer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 6.  Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies.

Authors:  Babette W Prick; Wim C J Hop; Johannes J Duvekot
Journal:  Am J Clin Nutr       Date:  2011-12-28       Impact factor: 7.045

7.  Maternal DNA hypomethylation and congenital heart defects.

Authors:  Shimul Chowdhury; Mario A Cleves; Stewart L MacLeod; S Jill James; Weizhi Zhao; Charlotte A Hobbs
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-01-19

Review 8.  The neurochemistry of phenylketonuria.

Authors:  R Surtees; N Blau
Journal:  Eur J Pediatr       Date:  2000-10       Impact factor: 3.183

9.  Maternal global methylation status and risk of congenital heart diseases.

Authors:  Lydi M J W van Driel; Robert de Jonge; Willem A Helbing; Bertrand D van Zelst; Jaap Ottenkamp; Eric A P Steegers; Regine P M Steegers-Theunissen
Journal:  Obstet Gynecol       Date:  2008-08       Impact factor: 7.661

10.  Research design, organization, and sample characteristics of the Maternal PKU Collaborative Study.

Authors:  Richard Koch; Colleen Azen; Eva Friedman; William Hanley; Harvey Levy; Reuben Matalon; Bobbye Rouse; Friedrich Trefz; Jiaping Ning; Felix de la Cruz
Journal:  Pediatrics       Date:  2003-12       Impact factor: 7.124

View more
  5 in total

1.  Frequency of the VNTR-Polymorphisms at the PAH Gene in the Iranian Azeri Turkish Patients with Phenylketonuria.

Authors:  Morteza Bagheri; Isa Abdi Rad; Nima Hosseini Jazani; Rasoul Zarrin; Ahad Ghazavi
Journal:  Maedica (Bucur)       Date:  2015-09

2.  Association Between PAH Mutations and VNTR Alleles in the West Azerbaijani PKU Patients.

Authors:  Morteza Bagheri; Isa Abdi Rad; Nima Hosseini Jazani; Rasoul Zarrin; Ahad Ghazavi
Journal:  Maedica (Buchar)       Date:  2014-09

3.  Maternal phenylketonuria in Turkey: outcomes of 71 pregnancies and issues in management.

Authors:  Yılmaz Yıldız; Hatice Serap Sivri
Journal:  Eur J Pediatr       Date:  2019-05-03       Impact factor: 3.183

Review 4.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

5.  Doxycycline hinders phenylalanine fibril assemblies revealing a potential novel therapeutic approach in phenylketonuria.

Authors:  Ada De Luigi; Alessandro Mariani; Massimiliano De Paola; Andrea Re Depaolini; Laura Colombo; Luca Russo; Valeria Rondelli; Paola Brocca; Lihi Adler-Abramovich; Ehud Gazit; Elena Del Favero; Laura Cantù; Mario Salmona
Journal:  Sci Rep       Date:  2015-10-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.